1 week Ago By ABMN Staff
Prudential Financial Inc. boosted its position in shares of Editas Medicine, Inc. ( NASDAQ:EDIT – Free Report ) by 35.
5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 196,977 shares of the company’s stock after purchasing an additional 51,600 shares during the quarter. Prudential Financial Inc.
owned about 0.24% of Editas Medicine worth $250,000 as of its most recent filing with the Securities & Exchange Commission. A number of other institutional investors and hedge funds have also bought and sold shares of the company.
Monaco Asset Management SAM purchased a new position in shares of Editas Medicine during the fourth quarter valued at $1,359,000. Raymond James Financial Inc. bought a new stake in shares of Editas Medicine in the 4th quarter valued at about $303,000.
Stifel Financial Corp lifted its position in shares of Editas Medicine by 37.9% in the 3rd quarter. Stifel Financial Corp now owns 624,876 shares of the company’s stock worth $2,131,000 after purchasing an additional 171,656 shares during the period.
Point72 Asset Management L.P. bought a new position in shares of Editas Medicine during the third quarter valued at approximately $366,000.
Finally, FMR LLC boosted its stake in shares of Editas Medicine by 110.7% during the third quarter. FMR LLC now owns 203,087 shares of the company’s stock valued at $693,000 after purchasing an additional 106,684 shares in the last quarter.
71.90% of the stock is owned by institutional investors. Wall Street Analyst Weigh In A number of equities analysts recently commented on the stock.
Barclays reduced their price objective on shares of Editas Medicine from $5.00 to $3.00 and set an “equal weight” rating for the company in a research note on Friday, December 13th.
Robert W. Baird decreased their price objective on Editas Medicine from $10.00 to $8.
00 and set an “outperform” rating for the company in a research note on Friday, December 13th. Evercore ISI cut their target price on Editas Medicine from $7.00 to $5.
00 and set an “outperform” rating on the stock in a research note on Monday, December 16th. Truist Financial lowered shares of Editas Medicine from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Finally, Stifel Nicolaus downgraded shares of Editas Medicine from a “buy” rating to a “hold” rating and cut their price objective for the stock from $11.
00 to $3.00 in a research report on Friday, December 13th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the company.
Based on data from MarketBeat, Editas Medicine presently has an average rating of “Hold” and a consensus target price of $6.83. Editas Medicine Stock Down 3.
5 % Shares of NASDAQ:EDIT opened at $1.11 on Friday. The business has a 50-day moving average price of $1.
46 and a 200-day moving average price of $1.98. The stock has a market cap of $92.
10 million, a price-to-earnings ratio of -0.43 and a beta of 2.16.
Editas Medicine, Inc. has a 52-week low of $0.91 and a 52-week high of $6.
77. Editas Medicine ( NASDAQ:EDIT – Get Free Report ) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($0.
55) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.16).
Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%.
The company had revenue of $30.60 million for the quarter, compared to analyst estimates of $37.17 million.
During the same period in the prior year, the business posted ($0.23) earnings per share. As a group, equities analysts anticipate that Editas Medicine, Inc.
will post -2.71 EPS for the current fiscal year. Editas Medicine Profile ( Free Report ) Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.
It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. Recommended Stories Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.
com's FREE daily email newsletter ..
